Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

The proprotein convertase subtilisin/kexin-type 9 (PCSK9) binds to low-density lipoprotein
receptors (LDLR), thereby trafficking them to lysosomes upon endocytosis and enhancing …

Abstract Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has revolutionized our
understanding of cholesterol homeostasis and added to our arsenal against atherosclerotic …

Background Cancer is emerging as a major problem globally, as it accounts for the second
cause of death despite medical advances. According to epidemiological and basic studies …

Low-density lipoprotein (LDL) cholesterol plays a pivotal role in the pathogenesis of
atherosclerotic cardiovascular disease (CVD). The discovery that proprotein convertase …

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted zymogen expressed
primarily in the liver. PCSK9 circulates in plasma, binds to cell surface low-density …

Abstract Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of
low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the …

PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL
cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL …

Lowering blood cholesterol levels efficiently reduces the risk of developing atherosclerotic
cardiovascular disease (ASCVD), including coronary artery disease (CAD), which is the …

Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly synthetized and released by
the liver, represents one of the key regulators of low-density lipoprotein cholesterol …